Group items tagged

In the pharmaceutical industry, maintaining strict hygiene standards is paramount to ensure the safety and efficacy of products. One of the critical components in achieving this goal is the utilization of sanitary clamps. These clamps play a vital role in securing various connections within pharmaceutical equipment, preventing contamination, and upholding sterile conditions. In this article, we delve into the reasons why sanitary clamps are indispensable for maintaining hygiene in pharmaceutical settings. Contamination Prevention Sanitary clamps serve as a crucial barrier against contamination in pharmaceutical environments. With stringent regulations governing pharmaceutical manufacturing, any compromise in hygiene can result in significant consequences, including product recalls and compromised patient safety. Sanitary clamps are designed to create secure and airtight connections between pipes, hoses, and other components, effectively sealing off potential entry points for contaminants such as bacteria, viruses, and particulate matter. By minimizing the risk of contamination, these clamps help pharmaceutical companies uphold the integrity of their products and adhere to regulatory standards. Moreover, the design of sanitary clamps ensures ease of cleaning and sterilization, further reducing the risk of cross-contamination between batches. Unlike traditional fastening methods that may harbor bacteria or residue, sanitary clamps feature smooth surfaces and minimal crevices, making them easier to sanitize. This not only enhances hygiene but also promotes efficiency in the cleaning process, allowing pharmaceutical manufacturers to maintain high levels of cleanliness without compromising production timelines. Overall, by preventing contamination and facilitating thorough cleaning, sanitary clamps play a crucial role in safeguarding the quality and safety of pharmaceutical products.

Britain has approved Novavax's Covid-19 vaccine for use in those 18 years of age and older, the country's medicines regulator said on Thursday (February 3), bringing a fifth coronavirus shot to its roster amidst the rapid spread of the Omicron variant. The vaccine, Nuvaxovid, was approved as a first and second dose as it met the required safety, quality and effectiveness standards, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) said in a statement. The British approval for Nuvaxovid comes days after the drugmaker filed for US authorisation of the vaccine following months of struggles with development and manufacturing problems, and follows a German backing earlier in the day. "We are continuing our vital safety work in monitoring the use of all Covid-19 vaccines, to ensure that their benefits in protecting people against Covid-19 disease continue to outweigh any risks," MHRA chief executive June Raine said.

American pharmaceutical giant Pfizer has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for its medication Etrasimod, marketed as Velsipity, used to treat people with moderately to severely active ulcerative colitis. Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) that causes inflammation and ulcers (sores) in the lining of the large intestine (colon) and rectum. The approved recommended dose for Velsipity is one 2 mg tablet to be taken once daily. For the first three days, it is advised to take the medication with food, and subsequently, it can be taken daily either with or without food. According to the regulator, the approval of the medication is based on evidence from two clinical studies, which showed that 26 per cent of patients taking etrasimod achieved clinical remission after 12 weeks of treatment compared with 11 per cent of those receiving placebo. The studies included more than 740 patients aged 16 years and over for whom standard treatment or other treatments did not work well enough or could not be used.